Communication of the meeting of Transparency Council No. 31/2025 on 23 July 2025 with resolutions

We invite you to read minutes of the meeting of Transparency Council No. 31/2025 on 23 July 2025 during which the following resolutions were adopted:

1. At its meeting on 23 July 2025, the Transparency Council adopted position No. 91/2025 on the eligibility of the healthcare service “Early detection program for lung cancer in people with an increased, defined risk of developing the disease, using low-dose computed tomography (LDCT)” as a guaranteed service;

2. At its meeting on 23 July 2025, the Transparency Council adopted position No. 92/2025 on the assessment of a foodstuff for special nutritional purposes PKU GMPro Mix In for the indication: dietary management of patients with phenylketonuria over 3 years of age;

3. At its meeting on 23 July 2025, the Transparency Council adopted position No. 93/2025 on the appraisal of drug Trodelvy (sacituzumab govitecan) under the drug program “Treatment of patients with breast cancer (ICD-10: C50)”;

4. At its meeting on 23 July 2025, the Transparency Council adopted position No. 94/2025 on the appraisal of drug Tecartus (brexucabtagene autoleucel) under the drug program B.12.FM. “Treatment of patients with B-cell lymphomas (ICD-10: C82, C83, C85)”;

5. At its meeting on 23 July 2025, the Transparency Council adopted position No.95/2025 on the appraisal of drug Buccolam (midazolam) indicated for: prolonged, acute seizures in adults;

6. At its meeting on 23 July 2025, the Transparency Council adopted position No. 96/2025 on the appropriateness of granting reimbursement for Intuniv (guanfacine) for ADHD and Tourette syndrome.

Transparency Council meeting protocol >>